to Symphogen. This new class of therapeutic antibodies could be effective in treating complex diseases such as cancer for it allows the combination of several treatment modalities in one drug. Recombinant multi-clonal antibodies, or mixtures of mAbs, could be advantageous for the following reasons: less sensitive to target diversification such as viral escape mutants hit multiple targets simultaneously create large immune complexes that activate effector functions create a higher density of antibodies on target surfaces enhancing downstream effector functions such as complement lysis, phagocytosis and antibody-dependent cell-mediated cytotoxicity Symplex technology Symplex Technology is a process used to discover antibodies that are customized from plasma cells for a particular therapeutic application, and it involves direct isolation of the antibody genes from the immune system. Symplex Process: Immune cells are isolated from the spleen of mice or purified from human blood B-lymphocytes are separated using differences in cell densities Cells are individually sorted and antibodies are isolated Symplex PCR uses reverse transcription Heavy and light chains are amplified and conservatively paired back together in natural configuration Each antibody is cloned, placed into a bacterial vector and stored in a library Antibodies are placed into a well (repertoire arraying) and the DNA is extracted and prepared DNA is transected to make protein and antibodies are cloned The cloned antibodies are placed into wells and specifically chosen for further development based on antibody expression Antibody of choice from the original gene pairs (conjugate pairs) is chosen by screening A fully human antigen-specific antibody is produced Sympress technology Sympress Technology is the manufacturing platform used to produce recombinant polyclonal antibodies in high yields. This technology enables the production of consistent mixtures of polyclonal antibodies with high batch-to-batch consistency at an industrial scale. Sympress Process: Antibodies are encoded on plasmids using Chinese hamster ovary cell lines Cells undergo transfection Cells where the antibody is most highly expressed are selected through fluorescent tagging Cell lines are preserved and stored in cell banks The individual cell lines encoding the highest quality antibodies are mixed and produced in high yields Sympress I Technology has been used to develop the product Sym001. Recently, Sympress II Technology has been developed, and it uses random gene integration to improve the expression yield. Major products Of the ten products that Symphogen is in the process of developing, two have completed pre-clinical phases and have entered clinical trials. Both Sym001 and Sym004 are in